Schonfeld Strategic Advisors’s Aligos Therapeutics ALGS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.02M Buy
+181,880
New +$1.05M ﹤0.01% 1556
2022
Q2
– Sell
-1,060
Closed -$57K – 2493
2022
Q1
$57K Buy
+1,060
New +$84.9K ﹤0.01% 2322
2021
Q1
– Sell
-1,187
Closed -$821K – 1758
2020
Q4
$821K Buy
+1,187
New +$578K 0.01% 875

Other funds holding ALGS

Schonfeld Strategic Advisors's ALGS Position: Q3 2026 in Review

Schonfeld Strategic Advisors opened a new position in Aligos Therapeutics (ALGS) in Q3 2026: 181,880 shares worth $1.02M. The stake represents ﹤0.01% of the portfolio and ranks #1556 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in ALGS as recently as Q1 2022.

Schonfeld Strategic Advisors first reported a position in ALGS in Q4 2020 and has held it in 3 quarters since. 36 funds tracked by Wall St. Rank hold ALGS as of Q3 2026.

  • Schonfeld Strategic Advisors held 181,880 shares of Aligos Therapeutics worth $1.02M as of Q3 2026.
  • Aligos Therapeutics was a new Schonfeld Strategic Advisors position in Q3 2026.
  • Aligos Therapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q3 2026, its #1556 holding.
  • Schonfeld Strategic Advisors first reported a position in Aligos Therapeutics in Q4 2020 and has held it in 3 quarters since.
  • 36 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q3 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.